Sphingolipids have long been known to play important roles in cellular metabolism and membrane biology, but the notion of sphingolipids as cellular signaling molecules has gained recognition only the last two decades. Bioactive sphingolipids, including ceramide, sphingosine and sphingosine 1-phosphate (S1P) are now appreciated as key regulators of multiple cellular processes, including cell proliferation, differentiation, apoptosis, and immune responses. Our Lab is studying the role of S1P metabolism in cancer and aging.

Sphingosine 1-Phosphate, G protein coupled receptors (GPCRs), Alzheimer's disease, prostate cancer, renal cell carcinoma, bladder cancer, osteosarcoma, chemotherapy, photodynamic therapy, hypoxia, bone microenvironment, metastasis, invasion/migration, mitosis, necroptosis

The team belongs to the GDR3545 'G Protein-coupled receptors : from physiology to drugs (RCPG-Physio-Med)' network created in 2012 and affiliated to the "section 28" of Pharmacology, bio-engineering, imaging and biotechnology from the CNRS.
Read more


March 7, 2019
2B9, a novel antibody to detect, quantify or localize low amounts of endogenous S1P1

Sphingosine 1-Phosphate receptor 1 is the target of the immunomodulating drug fingolimod (FTY720) used for the treatment of multiple sclerosis (MS), which affects over 2.5 million patients worldwide. Its mechanism of action involves its phosphorylation into FTY720-P that binds to S1P1 leading to the inhibition of T lymphocyte egress from secondary lymphoid tissues and thymus to inflammatory sites.
The lack of specific antibodies against S1P1 has hampered the fine understanding of its role and localization, in particular under pathological conditions. This new antibody will help the community in validating data obtained in basic, translational and clinical research on MS.
by Franck Talmont et al. in PloS One
Read more

July 18-19, 2018
PIREPRED consortium organized its third scientific event in Pamplona

Scientific Organization: Félix Sanchez Valverde (Complejo Hospitalario de Navarra)
Pirepred coordinator: Javier Sancho (IUI BIFI, Universidad de Zaragoza).
The program can be consulted

Stacks Image 754

Stacks Image 763

January 27, 2018
Sphingosine kinase-2 expression and localization is altered in Alzheimer’s Disease

In a cohort of 25 post-mortem brain tissues from Alzheimer's disease patients, our results show a correlation between amyloid deposits and a loss of cytosolic SphK2 expression associated with a rise of nuclear cleaved SphK2.
by Gaëlle Dominguez et al. in Acta Neuropathologica Comm
Read more

Stacks Image 642

January 18-19, 2018
PIREPRED consortium organized its second scientific event in Barcelona

Scientific Organization: Xavier de la Cruz (ICREA-VHIR,
Vall d'Hebron Research Institute).
Pirepred coordinator: Javier Sancho (IUI BIFI, Universidad de Zaragoza).
The program can be consulted

Stacks Image 655

July 6-7, 2017
PIREPRED consortium organized its first scientific event in Bilbao on genetics and therapeutic approaches on rare diseases

The Pirepred 1st Scientific Event has been held after the third follow-up meeting, in the afternoon of July the 6th and in the morning of the 7th.
Organizing committee:
Scientific Organization: Juan Fernández-Recio (IBMB-CSIC, Barcelona Supercomputing Center).
Local Organization: Koldo Aldámiz-Echevarría (BioCruces).
Pirepred coordinator: Javier Sancho (IUI BIFI, Universidad de Zaragoza).
The program can be consulted

Stacks Image 549

April 23-25, 2017
French Society of Angiogenesis

On behalf of the French Society of Angiogenesis, the Lab co-organizes the 7th Meeting of the French Society of Angiogenesis in Toulouse from April 23 to April 25.
Read more
Stacks Image 106

March 28, 2017
Chromosome segregation and mitotic progression are regulated by S1P5 signaling

Our findings describe a novel unexpected function for S1P signaling and the underlying molecular mechanism by which it regulates mitotic progression and chromosome segregation.
by Guillaume Andrieu et al. in Science Signaling
Read more

Stacks Image 386

Cover story:
Mitotic signals through S1P
Targeting the signaling lipid S1P might suppress tumor growth by slowing mitosis

Jan 16, 2017
PIREPRED consortium meeting in Toulouse
El 16 de enero de 2017 se celebró en las instalaciones del Institute of Pharmacology and Structural Biology (IPBS) en Toulouse la segunda reunión del proyecto Pirepred. Se llevó a cabo dentro del marco de trabajo indicado en la agenda prevista. En la jornada tuvieron lugar 2 tipos de sesiones, unas conjuntas con la participación de todos los asistentes y otras, celebradas en paralelo (y en paralelo al lunch), reuniendo en un grupo a los participantes bioinformáticos y en otra a los participantes clínicos.

Tras estas, se puso en común los temas tratados, llevando así hacia la clausura de la reunión por parte del coordinador.

La opinión general de la intensa jornada de trabajo fue muy satisfactoria, con avances importantes en las acciones planificadas en Pirepred y un montón de trabajo a desarrollar a lo largo de los siguientes meses entre los socios.

La siguiente reunión, tercera ya de Pirepred se celebrará a mediados del 2017 en Biocruces, Barakaldo (Bilbao), sede de uno de los socios asociados implicados en el proyecto.
Stacks Image 567

Stacks Image 574

Oct 5, 2016
PIREPRED consortium meeting in Zaragoza

Stacks Image 116
Hospitales y centros de investigación de ambos lados del Pirineo se unen para mejorar los programas de cribado neonatal
Pirepred permitirá que hospitales y centros de investigación de ambos lados del Pirineo se unan para mejorar los programas de cribado neonatal. Así, desarrollará herramientas bioinformáticas de diagnóstico genético que ayuden a un pronóstico personalizado lo antes posible. El proyecto europeo está dotado con 827.000 euros para tres años.

Stacks Image 122

Des hôpitaux et des centres de recherche des deux côtés des Pyrénées s’associent pour améliorer les programmes de dépistage néonatal
Le projet Pirepred va permettre à des hôpitaux et des centres de recherche des deux côtés des Pyrénées de se réunir pour améliorer les programmes de dépistage néonatal.
Ainsi, de nouveaux outils de diagnostic génétique bioinformatiques seront développés pour permettre une prévision personnalisée des maladies néonatales dès que possible. Ce projet européen est doté de 827.000 euros pour trois ans.

July 20, 2016
FTY720 (Fingolimod) inhibits HIF-1 and HIF-2 signaling, and sensitizes to chemotherapy in renal cell carcinoma
Our findings establish that FTY720 (Fingolimod) blocks HIF-1 and HIF-2 accumulation in cell and animal model of ccRCC and sensitize to chemotherapy.
by Cécile Gstalder et al. in Mol Cancer Ther
Read more

Stacks Image 137

May 11, 2016
The Sphingolipid in Cancer & Aging Lab is a partner of the PIREPRED consortium funded by POCTEFA action
Este proyecto está cofinanciado por el Fondo Europe de Desarrollo Regional (FEDER)/ Ce projet est cofinancé par le Fonds Européen de Développement Régional (FEDER).
Read more

Stacks Image 513

January 26, 2016
The SphK1/S1P/S1P1 signaling regulates HIF-2α activity in cancer
Our work establishes the essential role of an autocrine signaling involving S1P1 in the regulation of HIF-2α expression and activity in cancer by the SphK1/S1P signaling. These findings demonstrate that S1P may act as a canonical regulator of HIF-2α expression in ccRCC, giving support to its inhibition as a therapeutic strategy that could contribute to reduce HIF-2 activity in ccRCC.
by Pierre Bouquerel et al. in Oncogenesis
Read more

Stacks Image 163

July 8, 2015
Cécile Gstalder PhD thesis defense
Cécile defended her PhD thesis, entitled ‘Rôle de la voie sphingosine kinase 1/sphingosine 1-phosphate
dans l’adaptation à l’hypoxie intratumorale
des adénocarcinomes rénaux à cellules claires
’. Prof. Catherine Muller (University of Toulouse) acted as the chair of the examination committee. The three discussants were: Prof. Alain Ravaud from the University of Bordeaux, Dr. François Vallette from University of Nantes and Dr. Fabrice Soncin from the University of Lille.
We wish Cécile all the best for her future career!

June 18-19, 2015
NEUROMED consortium final meeting & closing workshop in Barcelona

Stacks Image 187

May 12-17, 2015
Cécile Gstalder, PhD student, will present her work at the Keystone Symposia on hypoxia, Dublin (Ireland)

Stacks Image 198

May 1, 2015
Catherine Mazerolles
It is with profound sadness that we report the death of our colleague Dr Catherine Mazerolles on April 28. She was 55.
Catherine, uropathologist at the Hôpitaux de Toulouse, was a member of our research team for over ten years. She will be sorely missed.

March 5-6, 2015
The NEUROMED consortium meets at IPBS
Next meeting in Barcelona, June 18-19

Stacks Image 220
January 12, 2015
S1P as a therapeutic target to tackle hypoxia
Our study demonstrates preclinical proof of concept in mice bearing orthotopic prostate tumors that a strategy aimed at neutralizing S1P with a monoclonal antibody could reduce intratumoral hypoxia and associated vascular network malfunction by enhancing blood perfusion to significantly improve delivery and efficacy of docetaxel, the standard chemotherapy for prostate cancer. Our findings encourage further clinical studies to assess whether optimized scheduling of anti-S1P treatment provide evidence for vessel normalization in cancer patients to identify those who might be benefit from a combination therapy with chemotherapy or radiotherapy.
by Isabelle Ader et al. in Oncotarget
Read more

Stacks Image 231

July 9, 2014
The Sphingolipid in Cancer & Aging Lab is a partner of the NEUROMED consortium funded by SUDOE action
Read more
El periodico de aragon

Stacks Image 244

April 14, 2014
A dual role for S1P in prostate bone microenvironment
Osteoblast-borne S1P promotes osteoblastic differentiation, and proliferation and survival of prostate cancer cells uncovering the importance of S1P in the bone microenvironment, which may open a novel area of study for the treatment of prostate bone metastasis by targeting S1P.
by Leyre Brizuela et al. in Mol Oncol
Read more

Stacks Image 257

January 27, 2014
S1P as a biomarker of Alzheimer’s Disease
Analysis of 56 human Alzheimer’s Disease human brains revealed a decrease in SphK1 expression whereas S1P lyase expression was increased, highlighting the importance of S1P and suggesting the existence of a global deregulation of S1P signaling in this neurodegenerative disease.
by Johnatan Ceccom et al. in Acta Neuropathologica Comm
Read more

Stacks Image 268

May 10, 2013
Interview of Olivier Cuvillier by the french newspaper ‘Le Figaro’ about chemoprevention and cancer
Read more

Stacks Image 279

March 11, 2013
The Innovative Models Initiative (IMODI) consortium laureate of the French Government’s Investing for the Future programme ‘Programme d’Investissements d’Avenir’.
The Sphingolipid in Cancer & Aging Lab is a member of the IMODI consortium for the characterization and validation of novel prostate cancer cell models
Read more

Stacks Image 290


+33 561 17 55 13

IPBS, Institute of Pharmacology and Structural Biology
205 Route de Narbonne - BP 64182
31077 Toulouse Cedex 4, France


Sphingosine kinases in articulate, bone-related and calcification diseases
El Jamal A, Bougault C, Mebarek S, Magne D, Cuvillier O, Brizuela L
Int J Mol Sci, upcoming

Sphingosine kinase-1 predicts overall survival outcome in non-small cell lung cancer patients treated with carboplatin and navelbine
Gachechiladze M, Tichy T, Kolek V, Grygarkova I, Klein J, Mgebrishvili G, Kharaishvili G, Janikova M, Smickova P, Cierna L, Pitson S, Maddelein ML, Cuvillier O*, Skarda J*
Oncology Letters, in press

Development and characterization of a novel sphingosine 1-phosphate receptor 1 monoclonal antibody suitable for cell imaging and biochemical studies of endogenous receptors
Talmont F, Moulédous L, Baranger M, Gomez-Brouchet A, Zajac JM, Deffaud C, Cuvillier O*, Hatzoglou A*
PLoS One, 14 (2019) e0213203

Pharmacomodulation on Gold-NHC Complexes for Anticancer Applications – is Lipophilicity the Key Point?
Zhang C, Maddelein ML, Wai-Yin Sun R, Gornitzka H*, Cuvillier O*, Hemmert C*
Eur J Med Chem, 157 (2018) 320-332

Neuronal Sphingosine kinase-2 subcellular localization is altered in Alzheimer's disease brain
Dominguez G, Maddelein ML, Pucelle M, Nicaise Y, Maurage CA, Duyckaerts C, Cuvillier O*, Delisle MB*
Acta Neuropathologica Comm, 6 (2018) 25

Cationic and neutral N-Heterocyclic Carbene Gold(I) complexes: cytotoxicity, NCI-60 screening, cellular uptake, inhibition of mammalian thioredoxin reductase and ROS formation
Zhang C, Hemmert C*, Gornitzka H*, Cuvillier O*, Zhang M, Wai-Yin R*
ChemMedChem, 13 (2018) 1218-1229

La Sphingosine 1-phosphate : un nouveau régulateur de la mitose
Cuvillier O, Hatzoglou A
Médecine/Sciences, 34 (2018) 112-114

Sphingosine 1-phosphate signaling controls mitosis
Cuvillier O, Hatzoglou A
Oncotarget, 8 (2017) 114414-114415

Sphingosine 1-phosphate signaling through its receptor S1P5 promotes chromosome segregation and mitotic progression
Andrieu G, Ledoux A, Branka S, Bocquet M, Walzer T, Kasahara, K, Inagaki M, Sabbadini RA, Cuvillier O*, Hatzoglou A*
Science Signaling, 10 (2017) eaah4007

The therapeutic potential of HIF-2 antagonism in Renal Cell Carcinoma
Cuvillier O
Transl Androl Urol, 6 (2017) 131-133

FTY720 (Fingolimod) inhibits HIF-1 and HIF-2 signaling, promotes vascular remodeling and chemosensitizes in renal cell carcinoma animal model
Gstalder C, Ader I, Cuvillier O
Mol Cancer Ther, 15 (2016) 2565-2574

Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations
Bousquet M, Noirot C, Accadbled F, Sales de Gauzy J, Castex MP, Brousset P, Gomez-Bouchet A
Ann Oncol, 27 (2016) 738-744

Essential role for SphK1/S1P signaling to regulate hypoxia-inducible factor 2a expression and activity in cancer
Bouquerel P, Gstalder C, Muller D, Laurent J, Brizuela L, Sabbadini RA, Malavaud B, Pyronnet S, Martineau Y, Ader I, Cuvillier O
Oncogenesis, 5 (2016) e209

Voiding dysfunction in mice with experimental autoimmune encephalomyelitis: a multiple sclerosis-like disease
Even L, Bouali O, Roumiguié M, Cuvillier O, Malavaud B, Game X
World J Nephron Urol, 5 (2016) 4-10

Mechanisms of castration resistance : intratumoral hypoxia stimulates the androgen receptor expression
Linardi P, Brizuela L, Beauval JB, Roumiguié M, Soulié M, Cuvillier O, Malavaud B
Prog Urol, 26 (2016) 159-167

Sphingomab, un anticorps anti-sphingosine 1-phosphate, comme agent anti-hypoxique dans le cancer
Cuvillier O
Médecine/Sciences, 31 (2015) 20-23

Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodeling and sensitizes to chemotherapy in prostate cancer
Ader I, Bouquerel P, Gstalder C, Golzio M, Andrieu G, Zalvidea S, Richard S, Malavaud B, Sabbadini RA, Cuvillier O
Oncotarget, 6 (2015) 13803-13821

Inhibition of Rac1-GTPase mediates the anti-migratory effects of metformin in prostate cancer cells
Dirat B, Ader I, Golzio M, Massa F, Mettouchi A, Laurent K, Larbret F, Malavaud B, Cormont M, Lemichez E, Cuvillier O, Tanti JF, Bost F
Mol Cancer Ther, 14 (2015) 586-596

Gem GTPase acts upstream Gmip/RhoA and regulates actin remodeling and spindle positioning in early mitosis
Andrieu G, Quaranta M, Leprince C, Cuvillier O, Hatzoglou A
Carcinogenesis, 35 (2014) 2503-2511

Synthesis, structures, and anticancer activities of gold (I) complexes involving N-heterocyclic carbene ligands
Boselli L, Ader I, Carraz M, Hemmert C*, Cuvillier O*, Gornitzka H*
Eur J Med Chem, 85 (2014) 87-94

Synthesis of fluorinated agonist of sphingosine 1-phosphate receptor 1
Aliouane L, Chao S, Brizuela L, Pfund E, Cuvillier O, Jean L, Renard PY, Lequeux T
Bioorg Med Chem, 22 (2014) 4955-4960

La sphingosine 1-phosphate comme biomarqueur de la maladie d'Alzheimer
Ceccom J, Delisle MB, Cuvillier O
Médecine/Sciences, 30 (2014) 493-495

Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells
Brizuela L, Martin C, Jeannot P, Ader I, Gstalder C, Andrieu G, Bocquet M, Laffosse JM, Gomez-Brouchet A, Malavaud B, Sabbadini RS, Cuvillier O
Mol Oncol, 8 (2014) 1181-1195

Sphingosine 1-phosphate and hypoxia signaling
Cuvillier O
in Molecular Mechanisms of Angiogenesis : from ontogenesis to oncogenesis, (Feige JJ, Pagès G and Soncin F, Eds.), Springer (2014) 199-217

Reduced sphingosine kinase-1 and enhanced sphingosine 1-posphate lyase expression demonstrate deregulated sphingosine 1-phosphate signaling in Alzheimer's disease
Ceccom J, Loukh N, Lauwers-Cances V, Touriol C, Nicaise Y, Gentil C, Uro-Coste E, Pitson S, Maurage CA, Duyckaerts C, Cuvillier O*, Delisle MB*
Acta Neuropathologica Comm, 2 (2014) 12

Polyphenols in prostate cancer
Brizuela L, Cuvillier O
in 'Polyphenols in health and disease', Academic Press, Vol 1 (2014) 1217-1230

Hypoxia, therapeutic resistance and sphingosine 1-phosphate
Cuvillier O, Ader I, Bouquerel P, Brizuela L, Gstalder C, Malavaud B
in 'Advances in Cancer Research, The role of sphingolipids in cancer development and therapy', Elsevier, Vol 117 (2013) 117-141

First evidence of sphingosine 1-phosphate lyase protein expression and activity in human neoplasm. Implication for resistance to therapeutics in prostate cancer
Brizuela L, Ader I, Mazerolles C, Bocquet M, Malavaud B, Cuvillier O
Mol. Cancer Ther, 11 (2012) 1841-1851

Les récepteurs à sphingosine 1-phosphate : de la biologie à la physio(patho)logie
Cuvillier O
Médecine/Sciences, 28 (2012) 953-959

La voie sphingosine kinase-1/sphingosine 1-phosphate dans l'hypoxie tumorale
Cuvillier O
VEGF Actu, 26 (2012) 6-8

Biochemical methods for quantifying sphingolipids : ceramide, sphingosine, sphingosine kinase-1 activity and sphingosine 1-phosphate
Brizuela L, Cuvillier O
in ‘Methods in Molecular Biology, S1P signaling Methods and Protocols’, Springer Science vol 874 (2012), 1-20

Biomarkers of aggressiveness in prostate cancer
Cuvillier O, Malavaud B
in ‘Prostate Cancer -Diagnosis and Therapeutic Advances', Intech Press (2011) 3-20

Hypoxia Inducible Factors and sphingosine 1-phosphate signaling
Cuvillier O, Ader I
Anticancer Agents Med Chem, 11 (2011) 854-862

Increased sphingosine kinase-1 expression and activity in prostate cancer resection specimens
Malavaud B, Pchejetski D, Mazerolles C, Russano de Paiva Silva G, Doumerc N, Calvet C, Pitson S, Rischmann P, Cuvillier O
Eur J. Cancer, 46 (2010) 3417-3424

FTY720 (Fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1
Pchejetski D, Brizuela L, Sauer L, Doumerc N, Golzio M, Salunkhe V, Teissié J, Malavaud B, Waxman J, Cuvillier O
Cancer Res., 70 (2010) 8651-8661

The sphingosine kinase-1 survival pathway : a potential target for tumor-suppressive tea and wine polyphenols in prostate cancer
Brizuela L, Dayon A, Doumerc N, Ader I, Golzio M, Izard JC, Hara Y, Malavaud B, Cuvillier O
Faseb J, 24 (2010) 3882-3894

Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting
Cuvillier O, Ader I, Bouquerel P, Brizuela L, Malavaud B, Mazerolles C, Rischmann P
Curr Mol Pharmacol, 3 (2010) 53-65

Sphingosine kinase-1 is a mediator of androgen-induced osteoblast cell growth
Martin C, Laffosse JM, Malavaud B, Cuvillier O
Biochem Biophys Res Comm, 391 (2010) 669-673

Sphingosine kinase inhibition sensitizes to hormone-resistant prostate cancer cells to docetaxel
Sauer L, Nunes J, Salunkhe V, Skalska L, Kohama T, Cuvillier O, Waxman J, Pchejetski D
Int J Cancer, 125 (2009) 2728-2736

Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival
Dayon A, Brizuela L, Martin C, Mazerolles C, Pirot N, Doumerc N, Nogueira L, Golzio M, Teissié J, Serre G, Rischmann P, Malavaud B, Cuvillier O
PLoS One, 4 (2009) e8048

When the sphingosine kinase-1/sphingosine 1-phosphate pathway meets hypoxia signaling: new targets for cancer therapy
Ader I, Malavaud B, Cuvillier O
Cancer Res, 69 (2009) 3723-3726

Targeting the sphingolipid metabolism to sensitize pancreatic cancer cell to gemcitabine
Guillermet J*, Davesne L*, Pchejetski D*, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, Delisle MB, Cuvillier O, Susini C, Bousquet C
Mol Cancer Ther, 8 (2009) 809-820

Chemosensitizing effect of sphingosine kinase-1 inhibition in prostate cancer cell and animal models
Pchejetski D, Doumerc N, Golzio M, Naymark M, Teissié J, Kohama T, Waxman J, Malavaud B, Cuvillier O
Mol Cancer Ther, 7 (2008) 1836-1845

Downregulating sphingosine kinase-1 for cancer therapy
Cuvillier O
Expert Opin Ther Targets, 12 (2008) 1009-1020

Sphingosine kinase-1 : a new modulator of HIF-1 during hypoxia in human cancer cells
Ader I, Brizuela L, Bouquerel P, Malavaud B, Cuvillier O
Cancer Res, 68 (2008) 8635-8642

Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells
Bonhoure E, Lauret A, Barnes DJ, Martin C, Malavaud B, Kohama T, Melo JV, Cuvillier O
Leukemia, 22 (2008) 971-979

Critical role for sphingosine kinase-1 in regulating survival of amyloid- peptide-treated neuroblastoma SH-SY5Y cells
Gomez-Brouchet A, Pchejetski D, Brizuela L, Garcia V, Altié MF, Maddelein ML, Delisle MB, Cuvillier O
Mol Pharmacol, 72 (2007) 341-349

Sphingosine kinase-1: a potential therapeutic target in cancer
Cuvillier O
Anticancer Drugs, 18 (2007) 105-110

Oxidative stress-dependent sphingosine kinase-1 inhibition mediates myocardiac cell apoptosis induced by MAO-A
Pchejetski D, Kundozova O, Dayon A, Calisse D, Seif I, Parini A, Cuvillier O
Circ Res, 100 (2007) 41-49
See comment : Circ. Res., 100 (2007) 7-9

Regulation by sphingosine 1-phosphate of Bax and Bad activities during apoptosis in a MEK1/2-dependent manner
Betito S, Cuvillier O
Biochem Biophys Res Comm, 341 (2006) 1273-1277

Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1
Bonhoure E, Pchejetski D, Aouali N, Levade T, Morjani H, Kohama T, Cuvillier O
Leukemia, 20 (2006) 95-102

Sphingosine kinase-1 as a sensor to chemotherapy in prostate adenocarcinoma cell and mouse models
Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, Mazerolles C, Rischmann P, Teissié J, Malavaud B, Cuvillier O
Cancer Res, 65 (2005) 11667-11675


Heinz Gornitzka, PhD & Catherine Hemmert, PhD
Laboratoire de Chimie de Coordination (CNRS), Toulouse
Christelle Hureau, PhD
Laboratoire de Chimie de Coordination (CNRS), Toulouse
Fernando Lecanda, PhD
Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain
Javier Sancho, PhD
Biocomputación y Fisica de Sistemas Complejos (BIFI), Zaragoza, Spain
Martine Cohen-Solal, MD/PhD
BIOSCAR UMR1132 (INSERM), Hôpital Lariboisière, Paris
Thierry Walzer, PhD
Centre International de Recherche en Infectiologie (INSERM/CNRS), Lyon
Claude-Alain Maurage, MD/PhD & Ariane Sharif, PhD
UMR_S1172 Centre Jean-Pierre Aubert (INSERM), Lille
Maryse Delehedde, PhD
SPQI, Lille


Permanent staff at IPBS

Olivier Cuvillier, PhD
Director of Research from the French National Institute of Health and Medical Research (INSERM)
Email :

Marie-Lise Maddelein, PhD
Senior Scientist from the French National Center for Scientific Research (CNRS)
Email :

Franck Talmont, PhD
Engineer from the French National Center for Scientific Research (CNRS)
Email :

Anastassia Hatzoglou, PhD
Professor from the University of Toulouse (UPS)
Email :

Non Permanent staff at IPBS

Pierre-Yves Fortin, PhD
Postdoctoral Fellow (CNRS)
Email :

Permanent staff at Oncopôle

Bernard Malavaud, MD, PhD
Urologist from the Institut Universitaire du Cancer Oncopôle (IUC) and Professor from the University of Toulouse
Email :

Anne Gomez-Brouchet, MD, PhD
Pathologist from the Institut Universitaire du Cancer Oncopôle (IUC) and Professor from the University of Toulouse
Email :


Interreg POCTEFA
Our Lab is a member of the PIREPRED consortium funded by POCTEFA action
Cofinanciado por el Fondo Europe de Desarrollo Regional (FEDER)
Cofinancé par le Fonds Européen de Développement Régional (FEDER).

Stacks Image 338

Investissements d’Avenir : Projets Structurants des Pôles de Compétitivité (BPI)
Our Lab is a member of the ‘IMODI’ consortium

Read more

Stacks Image 358

Association pour la Recherche sur les Tumeurs de la Prostate (ARTP)


Stacks Image 632

Cancéropôle Grand Sud Ouest
Our Lab is the partner of the Laboratoire de Chimie de Coordination

Stacks Image 729
Ligue Nationale contre le Cancer
Our Lab is the partner of the Laboratoire de Chimie de Coordination

Stacks Image 796


Stacks Image 499